

Autologous serum eye drops preparation: approach to the filtration step impact on the concentration of active molecule

Pauline Moncassin, Colin Margot, Hantz Sébastien, Ratsimbazafy Voa, Jérémy Jost

▶ To cite this version:

Pauline Moncassin, Colin Margot, Hantz Sébastien, Ratsimbazafy Voa, Jérémy Jost. Autologous serum eye drops preparation: approach to the filtration step impact on the concentration of active molecule. 28th EAHP Congress, Mar 2024, BORDEAUX, France. hal-04560732

HAL Id: hal-04560732 https://unilim.hal.science/hal-04560732

Submitted on 26 Apr 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.





Autologous serum eye drops preparation: approach to the filtration step impact on the concentration of active molecule



MONCASSIN Pauline⁽¹⁾, COLIN Margot⁽¹⁾, BERNIKIER Edouard⁽¹⁾, JOST Jeremy^(1,5), HANTZ Sébastien⁽²⁾, ROCHER Maxime⁽³⁾, FAYE Pierre-Antoine⁽⁴⁾, RATSIMBAZAFY Voa^(1,5) Department of ¹Pharmacy, ² Bacteriology-Virology, ³ Ophtalmology, ⁴ Biochemistry, ⁵ Research Unit EpiMaCT, Inserm U1094, IRD UMR270, INRAE USC 1051, University of Limoges and C.H.U Limoges, FRANCE

Autologous serum eye drops (ASEDs) are pharmaceutical preparations used in severe dry eye diseases. Sterility is a specification for eye drops, which can be obtained by filtration. Any molecule with a mean diameter greater than the filter porosity is then generally retained. EGF (Epidermal Growth Factor) is one of these active molecules (AMs) in ASEDs. With an intermediate molecular mass (MM) (180 kDa), its investigation make possible to predict the impact of filtration on the concentration of other active molecules.

OBJECTIVES: To evaluate the impact of this sterilisation method on AMs by measuring EGF concentrations before/after filtration of collected sera.

Four 4mL tubes of human serum (numbered from 1 to 4: P1-P4) were used, all from the hospital biological collection.


Each serum underwent the following 3 successive operations:

- **Zero filtration**
- Clarifying filtration (CF, at 0.45 µm porosity)
- Sterilising filtration (SF, at 0.20 µm porosity)

The assay was performed in duplicate using an ELISA technique (Quantikine® Human EGF Immunoassay kit, R&D System, USA). The impact of filtration is considered significant if the relative difference in concentrations after the process exceeds 7.5%.

The EGF concentration (pg/mL) in each unfiltered serum represents the maximum concentration (100%), allowing the impact of filtrations to be expressed as relative percentages of this maximum.





	Zero filtration	Clarifying filtration	Reduction	Sterilising filtration	Reduction
P1	100%	96.2%	3.8%	94.8%	5.2%
P2	100%	97.2%	2.8%	93.4%	6.6%
P3	100%	92.8%	7.2%	91.1%	8.9%
P4	100%	97.1%	2.9%	95.9%	4.1%

As expected, EGF concentrations decrease after filtration, especially when the porosity of the filter used is low. Moreover, the significance threshold is reached for P3 under SF.

We may suppose that smaller AMs (ie IGF-1, MM 7.6 kDa; TGF-β1, MM 25 kDa) will be less retained. For larger AMs such as fibronectin (MM around 450kDa), the decrease in concentration is likely to have an impact on the ASEDs efficacy, justifying a more specific study. Other methods of ensuring the microbiological safety of ASEDs should probably also be considered.